Volume 8, Supplement 2 (Sep/Oct 2017)

The development of tumor-targeted chimeric antigen receptor (CAR)–modified T cells has demonstrated the potential of this therapy for certain patients with refractory or relapsed leukemias and lymphomas. This article discusses the design of first- and second-generation CARs, their proposed MOAs, and key associated toxicities. As clinical use of this technology progresses, advanced practitioners will need to understand the biology underlying CAR T-cell therapy and play crucial roles in managing treatment-related toxicities.